Abstract
Background: Hilar cholangiocarcinoma accounts for 60% of cholangiocarcinomas from an anatomic point of view, followed by 30% of extrahepatic and 10% of intrahepatic. Curative resection represents the only hope for cure; however, more than 60% patients diagnosed of hilar cholangiocarcinoma were deemed unresectable, many with insufficient future liver remnant (FLR). We present a case underwent hepatico-pancreaticoduodenectomy (HPD) who had received neoadjuvant chemotherapy while waiting for an optimal hypertrophy of FLR after percutaneous transhepatic portal vein embolization (PTPE).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.